北京大学学报(医学版)
北京大學學報(醫學版)
북경대학학보(의학판)
JOURNAL OF BEIJING MEDICAL UNIVERSITY(HEALTH SCIENCES)
2014年
3期
405-411
,共7页
傅志英%朱军%宋玉琴%刘卫平%季新强%詹思延
傅誌英%硃軍%宋玉琴%劉衛平%季新彊%詹思延
부지영%주군%송옥금%류위평%계신강%첨사연
预后%淋巴瘤,大B细胞%弥漫性%Kaplan-Meiers评估
預後%淋巴瘤,大B細胞%瀰漫性%Kaplan-Meiers評估
예후%림파류,대B세포%미만성%Kaplan-Meiers평고
Prognosis%Lymphoma%large B-cell diffuse%Kaplan-Meiers estimate
目的:描述弥漫大B细胞淋巴瘤( diffuse large B cell lymphoma , DLBCL)的临床特征、生存情况,探讨预后相关因素。方法:回顾性分析1995年1月至2008年12月在北京大学肿瘤医院初治、资料完整的DLBCL病例。构建Kaplan-Meier生存曲线,估计5年总生存率,对选取的参数进行单因素分析,各组生存率(时期生存率)比较用Log-rank 检验;各因素5年生存率(时点生存率)的比较用U检验,采用Cox模型对单因素分析有统计学意义的参数进行多因素回归分析(采用后退法),多因素分析以双侧95%CI为统计标准,Cox模型中以P<0.05为差异有统计学意义。结果:共收集到资料完整的DLBCL病例525例,其中男性294例(56.0%),女性231例(44.0%)。发病中位年龄55(16~90)岁,>60岁者194例(37.0%)。 Ann Arbor分期:Ⅰ期54例(10.3%)、Ⅱ期152例(28.9%)、Ⅲ期117例(22.3%)、Ⅳ期202例(38.5%)。起病时有 B 症状者206例(39.2%),血清 LDH 升高者192例(36.6%)。治疗过程中联合利妥昔单抗(rituximab,R)和未联合利妥昔单抗(non-R)治疗的病例分别为197例(37.5%)和328(62.5%)。全组中位随访时间77.5(0~205)个月,中位总生存期84个月,5年总生存率52.3%。无论单因素分析还是多因素分析均显示以下因素具有统计学意义:年龄60岁分界、性别、Ann Arbor分期、有无B症状、血清LDH升高与否、治疗中是否联合利妥昔单抗( R组和non-R组)。相对风险度( RR)分别为:RR(发病年龄>60岁/≤60岁)=1.380(95%CI 1.078~1.765),RR(男性/女性)=1.315(95%CI 1.025~1.687),RR(Ⅲ期/Ⅰ期)=3.034(95%CI 1.667~5.522),RR(Ⅳ期/Ⅰ期)=3.748(95%CI 2.102~6.681)、RR(有B症状/无B症状)=1.278(95%CI 0.999~1.636)、RR(血清LDH水平未升高/升高)=1.351(95%CI 1.057~1.726),RR(non-R/R)=1.543(95%CI 1.182~2.015)。将年龄分界下移到50岁,单因素与多因素分析显示其可预测预后,RR=1.478(95%CI 1.148~1.902),P=0.002。结论:性别、年龄、初诊分期、B症状、LDH水平、是否使用利妥昔单抗治疗与DLBCL的预后存在关系;与IPI评分系统相比,性别、年龄分界下移到50岁、B症状可能是中国DLBCL患者比较独特的预后因素,但仍需大样本、多中心、多地区数据进一步研究。
目的:描述瀰漫大B細胞淋巴瘤( diffuse large B cell lymphoma , DLBCL)的臨床特徵、生存情況,探討預後相關因素。方法:迴顧性分析1995年1月至2008年12月在北京大學腫瘤醫院初治、資料完整的DLBCL病例。構建Kaplan-Meier生存麯線,估計5年總生存率,對選取的參數進行單因素分析,各組生存率(時期生存率)比較用Log-rank 檢驗;各因素5年生存率(時點生存率)的比較用U檢驗,採用Cox模型對單因素分析有統計學意義的參數進行多因素迴歸分析(採用後退法),多因素分析以雙側95%CI為統計標準,Cox模型中以P<0.05為差異有統計學意義。結果:共收集到資料完整的DLBCL病例525例,其中男性294例(56.0%),女性231例(44.0%)。髮病中位年齡55(16~90)歲,>60歲者194例(37.0%)。 Ann Arbor分期:Ⅰ期54例(10.3%)、Ⅱ期152例(28.9%)、Ⅲ期117例(22.3%)、Ⅳ期202例(38.5%)。起病時有 B 癥狀者206例(39.2%),血清 LDH 升高者192例(36.6%)。治療過程中聯閤利妥昔單抗(rituximab,R)和未聯閤利妥昔單抗(non-R)治療的病例分彆為197例(37.5%)和328(62.5%)。全組中位隨訪時間77.5(0~205)箇月,中位總生存期84箇月,5年總生存率52.3%。無論單因素分析還是多因素分析均顯示以下因素具有統計學意義:年齡60歲分界、性彆、Ann Arbor分期、有無B癥狀、血清LDH升高與否、治療中是否聯閤利妥昔單抗( R組和non-R組)。相對風險度( RR)分彆為:RR(髮病年齡>60歲/≤60歲)=1.380(95%CI 1.078~1.765),RR(男性/女性)=1.315(95%CI 1.025~1.687),RR(Ⅲ期/Ⅰ期)=3.034(95%CI 1.667~5.522),RR(Ⅳ期/Ⅰ期)=3.748(95%CI 2.102~6.681)、RR(有B癥狀/無B癥狀)=1.278(95%CI 0.999~1.636)、RR(血清LDH水平未升高/升高)=1.351(95%CI 1.057~1.726),RR(non-R/R)=1.543(95%CI 1.182~2.015)。將年齡分界下移到50歲,單因素與多因素分析顯示其可預測預後,RR=1.478(95%CI 1.148~1.902),P=0.002。結論:性彆、年齡、初診分期、B癥狀、LDH水平、是否使用利妥昔單抗治療與DLBCL的預後存在關繫;與IPI評分繫統相比,性彆、年齡分界下移到50歲、B癥狀可能是中國DLBCL患者比較獨特的預後因素,但仍需大樣本、多中心、多地區數據進一步研究。
목적:묘술미만대B세포림파류( diffuse large B cell lymphoma , DLBCL)적림상특정、생존정황,탐토예후상관인소。방법:회고성분석1995년1월지2008년12월재북경대학종류의원초치、자료완정적DLBCL병례。구건Kaplan-Meier생존곡선,고계5년총생존솔,대선취적삼수진행단인소분석,각조생존솔(시기생존솔)비교용Log-rank 검험;각인소5년생존솔(시점생존솔)적비교용U검험,채용Cox모형대단인소분석유통계학의의적삼수진행다인소회귀분석(채용후퇴법),다인소분석이쌍측95%CI위통계표준,Cox모형중이P<0.05위차이유통계학의의。결과:공수집도자료완정적DLBCL병례525례,기중남성294례(56.0%),녀성231례(44.0%)。발병중위년령55(16~90)세,>60세자194례(37.0%)。 Ann Arbor분기:Ⅰ기54례(10.3%)、Ⅱ기152례(28.9%)、Ⅲ기117례(22.3%)、Ⅳ기202례(38.5%)。기병시유 B 증상자206례(39.2%),혈청 LDH 승고자192례(36.6%)。치료과정중연합리타석단항(rituximab,R)화미연합리타석단항(non-R)치료적병례분별위197례(37.5%)화328(62.5%)。전조중위수방시간77.5(0~205)개월,중위총생존기84개월,5년총생존솔52.3%。무론단인소분석환시다인소분석균현시이하인소구유통계학의의:년령60세분계、성별、Ann Arbor분기、유무B증상、혈청LDH승고여부、치료중시부연합리타석단항( R조화non-R조)。상대풍험도( RR)분별위:RR(발병년령>60세/≤60세)=1.380(95%CI 1.078~1.765),RR(남성/녀성)=1.315(95%CI 1.025~1.687),RR(Ⅲ기/Ⅰ기)=3.034(95%CI 1.667~5.522),RR(Ⅳ기/Ⅰ기)=3.748(95%CI 2.102~6.681)、RR(유B증상/무B증상)=1.278(95%CI 0.999~1.636)、RR(혈청LDH수평미승고/승고)=1.351(95%CI 1.057~1.726),RR(non-R/R)=1.543(95%CI 1.182~2.015)。장년령분계하이도50세,단인소여다인소분석현시기가예측예후,RR=1.478(95%CI 1.148~1.902),P=0.002。결론:성별、년령、초진분기、B증상、LDH수평、시부사용리타석단항치료여DLBCL적예후존재관계;여IPI평분계통상비,성별、년령분계하이도50세、B증상가능시중국DLBCL환자비교독특적예후인소,단잉수대양본、다중심、다지구수거진일보연구。
Objective:To describe the clinical characteristics , overall survival as well as to evaluate the prognostic factors in Chinese diffuse large B cell lymphoma ( DLBCL) patients.Methods: DLBCL pa-tients who were initially diagnosed and treated in Peking University Cancer Hospital from January 1995 to December 2008 were identified and analyzed ,retrospectively .The 5-year OS rates were estimated with Ka-plan-Meier.Log-rank test was used to compare the survival curves of the different groups .The multivari-ate analysis of prognostic factors was conducted with Cox regression model , which included all statistically significant prognostic factors in the univariate analyses .Results:A total of 525 DLBCL patients were in-cluded in this retrospective analysis , of whom , 294 were male and 231 female ( male∶female=1 .27∶1 ) . The median age at the initial diagnosis was 55 (range 16-90) years, and 37.0% (n=194) were 60 years and above .Regarding the clinical staging at the initial diagnosis , 54 patients (10.3%) were diag-nosed as Stage Ⅰ of the disease, 152 (28.9%) as Stage Ⅱ, 117 (22.3%) as Stage Ⅲ and 202 (38.5%) as Stage Ⅳ.The ‘B symptoms’ and increased serum LDH were presented in 206 (39.2%) and 192 (36.6%) patients, respectively.A total of 197 (37.5%) patients were treated with rituximab (R).The survival follow-up continued till 31 January 2014 with a median follow-up time of 77.5 ( range:0-205) months.A total of 267 patients (50.9%) died during the follow-up period.The medi-al overall survival ( OS) time was 84 months, and 5-year OS rate was 52.3%.There were six statistically significant prognostic factors that were identified in both univariate and multivariate analyses : gender, Ann Arbor stage, B symptom, serum LDH, age at initial diagnosis and rituximab treatment .The relative risk ( RR) of these prognostic factors in the multivariate analyses were: age >60 years /≤60 years=1.380 (95%CI 1.078 -1.765), male /female =1.315 (95%CI 1.025 -1.687), stage Ⅲ/stageⅠ=3.034(95%CI 1.667-5.522), stage Ⅳ/Ⅰ=3.748(95%CI 2.102 -6.681), with B symp-toms/without B symptoms=1.278(95%CI 0.999-1.636),serum LDH increased/LDH not increased=1.351(95%CI 1.057 -1.726), without R treatment /with R treatment =1.543(95%CI 1.182 -2 .015 ) .Compared with the IPI , age >50 years/≤50 years was a statistically significant factor in both univariate and multivariate analyses RR =1.478 (95%CI 1.148-1.902), P=0.002.Conclusion:Six factors were related to DLBCL survival:gender, Ann Arbor stage, B symptom, serum LDH, age at initial diagnosis and rituximab treatment .Compared with the IPI , several specific factors may predict a poor prognosis in Chinese DLBCL patients:male , age>50 years and the presence of ‘B symptoms ’ .But this result is not conclusive until these factors are further tested .